menu
    • menu
    [{"orgOrder":0,"company":"iRegene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Dopaminergic Progenitor Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"iRegene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"iRegene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"iRegene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"iRegene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Human Dopaminergic Progenitor Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"iRegene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"iRegene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"iRegene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"iRegene Therapeutics","sponsor":"Northern Light Venture Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Series B Financing","leadProduct":"NN001","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"iRegene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"iRegene Therapeutics \/ Northern Light Venture Capital","highestDevelopmentStatusID":"8","companyTruncated":"iRegene Therapeutics \/ Northern Light Venture Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by iRegene Therapeutics

    Menu

    iRegene Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            iRegene Therapeutics

                            China arrow
                            The MedTech Conference
                            Not Confirmed

                            iRegene Therapeutics

                            China arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NN001

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Northern Light Venture Capital

                            Deal Size : Undisclosed

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            iRegene Secures Series B+ Financing Following FDA Fast Track Designation for NouvNeu001

                            Details : The proceeds will be used to accelerate iRegene's global clinical development of NouvNeu001, the world's first clinical-stage, iPSC-derived, allogeneic dopaminergic progenitor cell therapy for PD.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            September 09, 2025

                            Lead Product(s) : NN001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Northern Light Venture Capital

                            Deal Size : Undisclosed

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            iRegene Therapeutics

                            China arrow
                            The MedTech Conference
                            Not Confirmed

                            iRegene Therapeutics

                            China arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Dopaminergic Progenitor Cell

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease

                            Details : Human Dopaminergic Progenitor Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 23, 2024

                            Lead Product(s) : Human Dopaminergic Progenitor Cell

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            iRegene Therapeutics

                            China arrow
                            The MedTech Conference
                            Not Confirmed

                            iRegene Therapeutics

                            China arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Dopaminergic Progenitor Cell

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease

                            Details : Human Dopaminergic Progenitor Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 12, 2023

                            Lead Product(s) : Human Dopaminergic Progenitor Cell

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth